Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
2018; American Association for the Advancement of Science; Volume: 10; Issue: 463 Linguagem: Inglês
10.1126/scitranslmed.aat5775
ISSN1946-6242
AutoresDionysos Slaga, Diego Ellerman, T. Noelle Lombana, Rajesh Vij, Ji Li, Maria Hristopoulos, Robyn Clark, Jennifer Johnston, Amy L. Shelton, Elaine Mai, Kapil Gadkar, Sadis Matalon, James T. Koerber, Klára Tótpál, Rodney A. Prell, Genee Lee, Christoph Spiess, Teemu T. Junttila,
Tópico(s)Immunotherapy and Immune Responses
ResumoT cell–dependent bispecific antibodies with bivalent low affinity binding to HER2 are more selective for tumor cells that overexpress the target.
Referência(s)